<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02583438</url>
  </required_header>
  <id_info>
    <org_study_id>Saxa015</org_study_id>
    <nct_id>NCT02583438</nct_id>
  </id_info>
  <brief_title>Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes</brief_title>
  <official_title>Beijing Chao-yang Hospital, Capital Medical University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intestinal microflora imbalance has been associated with obesity and type 2 diabetes. The&#xD;
      researchers' study aimed to investigate the effect of saxagliptin on gut microbiota in&#xD;
      patients with newly diagnosed type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>gut microbiota</measure>
    <time_frame>Change from Baseline Bacteroidetes abundances and composition of gut microbiota at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The improvement of intestinal microflora imbalance</measure>
    <time_frame>Bacteroidetes abundances and composition of gut microbiota (baseline, 4 weeks, 8 weeks and 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of inflammatory markers</measure>
    <time_frame>The change of inflammatory markers (baseline, 12 weeks)</time_frame>
    <description>The effect on plasma levels of inflammatory markers, such as IL-1B, IL-6 and TNF-α(baseline, 12 weeks)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Lifestyle intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin (Bristol-Myers Squibb Company)</intervention_name>
    <description>6-month treatment of Saxagliptin 5mg Qd</description>
    <arm_group_label>Lifestyle intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females or males, and aged 20 to 65 years.&#xD;
&#xD;
          -  Newly diagnosed type 2 diabetes&#xD;
&#xD;
          -  HbA1C ≥7% and HbA1C &lt;9%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hepatic insufficiency (ALT or AST&gt; 1.5*ULN)&#xD;
&#xD;
          -  Renal insufficiency [Creatinine clearance rate (Ccr)]&lt;60ml/min estimated from MDRD&#xD;
             equation)&#xD;
&#xD;
          -  Coronary artery disease&#xD;
&#xD;
          -  Thyroid disease&#xD;
&#xD;
          -  Infectious disease&#xD;
&#xD;
          -  Systemic inflammatory disease&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Subjects who were taking agents known to influence gut microbiota&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Other conditions at investigator's discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 14, 2015</study_first_submitted>
  <study_first_submitted_qc>October 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Guang Wang</investigator_full_name>
    <investigator_title>Department of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Gut Microbiota</keyword>
  <keyword>inflammatory marker</keyword>
  <keyword>Glucose and lipid metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

